Skip to main content

Table 1 Characteristics of the 666 children and adolescents enrolled in the EnPRISE study, 2015, Senegal

From: High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal

Characteristics n n % %
N 666    
Gender (n = 666)
 Girl 328   49%  
Age (n = 666)
 < 5 years 159   24%  
 5–10 years 253   38%  
 10–14 years 213   32%  
 > 14 years 41   6%  
Education (n = 666)
 No formal education 235   35%  
 Educated 431   65%  
  Primary   255   59%
  Arabic-Koranica   99   23%
  Secondary   47   11%
  Unavailable   30   7%
Family status (n = 666)
 Both parents alive 273   41%  
 One parent alive 292   44%  
 Orphans of both parents 101   15%  
Testing of siblings (n = 666)
 No siblings 82   13%  
 Siblings 485   72%  
  No one tested 135   28%  
  At least one tested 140   29%  
  All tested 210   43%  
 Unavailable 99   15%  
Type of facility b (n = 666)
 Health Center 322   48%  
 Level-I Hospital 141   21%  
 Level-II Hospital 196   30%  
 Level-III Hospital 7   1%  
Responsible for treatment (n = 666)
 General practitioner 432   65%  
 Pediatrician 234   35%  
Disclosure (n = 666)
 Children < 8 years (not notified) 243   37%  
 Age ≥ 8 years 300   45%  
  Notified of status 42   14%  
  Not notified of status 258   86%  
 Unavailable 123   18%  
Gateway to care c (n = 666)
 Care 347   52%  
 Familial 270   40%  
 PMTCT 12   2%  
 Unavailable 37   6%  
Regularity of follow-up d (n = 666)
 Regular 482   72%  
 Not regular 128   19%  
 Unavailable 56   9%  
Prolonged treatment interruptions e (n=666)
 Yes 75   11%  
 No 586   88%  
 Unavailable 5   1%  
Nutritional status f (n = 666)
 Normal 393   59%  
 Moderate acute malnutrition (MAM) 95   14%  
 Severe acute malnutrition (SAM) 87   13%  
 Overweight 28   4%  
 Unavailable 63   10%  
Exposure to PMTCT (n = 666)
 Yes 45   7%  
 No 468   70%  
 Age < 10 years 412   88%  
 Age ≥ 10 years 56   12%  
 Unavailable 153   23%  
ART Therapy (n = 666)
 Children untreated 65   10%  
 Children treated 601   90%  
Viral load (n = 666)
 Treatment ≤6 months 103   17%  
 Treatment > 6 months 498   83%  
 < 1000 cp/mL   178   36%
 ≥1000 cp/mL   320   64%
Duration of follow-up (treatment > 6 months n = 498)
 6–12 months 110   22%  
 13–24 months 113   23%  
 >  24 months 275   55%  
Treatment regimen (treatment > 6 months n = 498) g
 AZT + 3TC + NVP/EFV 425   85%  
 Other NRTI+NNRTI combinations 37   8%  
 Combination with PI 36   7%  
Adherence h (all children on treatment n = 601)
 Good 372   61%  
 Average 81   13%  
 Poor 61   10%  
 Unavailable 87   14%  
  1. aFranco-Arabic/Koranic schools based on the study of the Koran and Arabic language
  2. bLevel-I Hospital, departmental level; Level-II Hospital, regional level; Level-III Hospital, national level
  3. cGateway to care: place of first consultation leading to HIV testing
  4. dRegularity of follow-up: quarterly
  5. eProlonged treatment interruptions: greater than one month
  6. fNutritional status: based on WHO criteria
  7. gTreatment regimen
  8. hAdherence: estimated by physician
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us